In line with the concept of metabolic intervention, alanyl-glutamine has been reported to reshape the gut microbiota, increase butyrate, activate AMP-activated protein kinase (AMPK) signaling, and inhibit the NLRP3 inflammasome, thereby alleviating inflammatory pathology in allergic asthma (Liu et al., 2020). This evidence concerns the gene NLRP3 and allergic asthma.